Effects of an angiotensin II receptor blocker on the impaired function of endothelial progenitor cells in patients with essential hypertension

American Journal of Hypertension

Volumn 27, Issue 5, 2014, Pages 695-701

  Suzuki, Ryo ^a   Fukuda, Noboru ^a,b   Katakawa, Mayumi ^a   Tsunemi, Akiko ^a   Tahira, Yoshiko ^a   Matsumoto, Taro ^a   Ueno, Takahiro ^a   Soma, Masayoshi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIHON UNIVERSITY   (Japan)

Author keywords

angiotensin II receptor blocker; blood pressure; colony formation; endothelial progenitor cell; essential hypertension; human; hypertension.

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; LOSARTAN; TRICHLORMETHIAZIDE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIURETIC AGENT;

ADULT; ARTICLE; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; ENDOTHELIAL PROGENITOR CELL; ESSENTIAL HYPERTENSION; FEMALE; HEART PROTECTION; HUMAN; HUMAN CELL; MALE; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; CELL CULTURE; CELL PROLIFERATION; DRUG EFFECTS; ENDOTHELIUM CELL; HYPERTENSION; JAPAN; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; STEM CELL; TIME; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CELL PROLIFERATION; CELLS, CULTURED; CROSS-OVER STUDIES; DIURETICS; ENDOTHELIAL CELLS; FEMALE; HUMANS; HYPERTENSION; JAPAN; LOSARTAN; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROSPECTIVE STUDIES; STEM CELLS; TIME FACTORS; TREATMENT OUTCOME; TRICHLORMETHIAZIDE;

EID: 84898898538     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpt208     Document Type: Article

References (25)

1. Fukuda N, Satoh C, Hu WY, Soma M, Kubo A, Kishioka H, Watanabe Y, Izumi Y, Kanmatsuse K. Production of angiotensin II by homogeneous cultures of vascular smooth muscle cells from spontaneously hypertensive rats. Arterioscler Tromb Vasc Biol 1999; 19:1210-1217.
2. Hsueh WA, Do YS, Anderson P W, Law RE. Angiotensin II in cell growth and matrix production. Adv Exp Med Biol 1995; 377:217-23.
3. Berry C, Brosnan MJ, Fennell J, Hamilton CA, Dominiczak AF. Oxidative stress and vascular damage in hypertension. Curr Opin Nephrol Hypertens 2001; 10:247-255.
4. Balin AK, Fisher AJ, Anzelone M, Leong I, Allen RG. Efects of establishing cell cultures and cell culture conditions on the proliferative life span of human fbroblasts isolated from diferent tissues and donors of diferent ages. Exp Cell Res 2002; 274:275-287.
5. Sanada S, Kitakaze M, Node K, Takashima S, Ogai A, Asanuma H, Sakata Y, Asakura M, Ogita H, Liao Y, Fukushima T, Yamada J, Minamino T, Kuzuya T, Hori M. Diferential subcellular actions of ACE inhibitors and AT(1) receptor antagonists on cardiac remodeling induced by chronic inhibition of NO synthesis in rats. Hypertension 2001; 38:404-411.
6. Yao EH, Fukuda N, Matsumoto T, Katakawa M, Yamamoto C, Tsunemi A, Suzuki R, Ueno T, Matsumoto K. Losartan improves the impaired function of endothelial progenitor cells in hypertension via an antioxi-dant efect. Hypertens Res 2007; 30:1119-1128.
7. Yu Y, Fukuda N, Yao EH, Matsumoto T, Kobayashi N, Suzuki R, Tahira Y, Ueno T, Matsumoto K. Efects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension. Am J Hypertens 2008; 21:72-77.
8. Yoshida Y, Fukuda N, Maeshima A, Yamamoto C, Matsumoto T, Ueno T, Nojima Y, Matsumoto K, Soma M. Treatment with valsartan stimulates endothelial progenitor cells and renal label-retaining cells in hypertensive rats. J Hypertens 2011; 29:91-101.
9. Hill JM, Zalos G, Halcox J P, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. New Eng J Med 2003; 348:593-600.
10. Kitiyakara C, Chabrashvili T, Chen Y, Blau J, Karber A, Aslam S, Welch WJ, Wilcox CS. Salt intake, oxidative stress, and renal expression of NADPH oxidase and superoxide dismutase. J Am Soc Nephrol 2003; 14:2775-2782.
11. Oliveras A, Soler MJ, Martínez-Estrada OM, Vázquez S, Marco-Feliu D, Vila JS, Vilaró S, Lloveras J. Endothelial progenitor cells are reduced in refractory hypertension. J Hum Hypertens 2008; 22:183-190.
12. Lee CW, Huang PH, Huang SS, Leu HB, Huang CC, Wu TC, Chen J W, Lin SJ. Decreased circulating endothelial progenitor cell levels and function in essential hypertensive patients with electrocardiographic lef ventricular hypertrophy. Hypertens Res 2011; 34:999-1003.
13. Bahlmann FH, de Groot K, Mueller O, Hertel B, Haller H, Fliser D. Stimulation of endothelial progenitor cells a new putative therapeutic efect of angiotensin II receptor antagonists. Hypertension 2005; 45:526-529.
14. Taddei S, Virdis A, Mattei P, Ghiadoni L, Gennari A, Fasolo CB, Sudano I, Salvetti A. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 1995; 91:1981-1987.
15. Hoogwerf BJ. Renin-angiotensin system blockade and cardiovascular and renal protection. Am J Cardiol 2010; 105:30A-35A.
16. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
17. Strawn WB, Richmond RS, Ann Tallant E, Gallagher PE, Ferrario CM. Renin-angiotensin system expression in rat bone marrow haematopoietic and stromal cells. Br J Haematol 2004; 126:120-126.
18. Rodgers KE, Xiong S, diZerega GS. Accelerated recovery from irradiation injury by angiotensin peptides. Cancer Chemother Pharmacol 2002; 49:403-411.
19. Endtmann C, Ebrahimian T, Czech T, Arfa O, Laufs U, Fritz M, Wassmann K, Werner N, Petoumenos V, Nickenig G, Wassmann S. Angiotensin II impairs endothelial progenitor cell number and function in vitro and in vivo: implications for vascular regeneration. Hypertension 2011; 58:394-403.
20. Heringer-Walther S, Eckert K, Schumacher SM, Uharek L, Wulf-Goldenberg A, Gembardt F, Fichtner I, Schultheiss H P, Rodgers K, Walther T. Angiotensin-(1-7) stimulates hematopoietic progenitor cells in vitro and in vivo. Haematologica 2009; 94:857-860.
21. Gallagher PE, Chappell MC, Ferrario CM, Tallant EA. Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes. Am J Physiol Cell Physiol 2006; 290:C420-C426.
22. Agata J, Ura N, Yoshida H, Shinshi Y, Sakaki H, Hyakkoky M, Taniguchi S, Shimamoto K. Olmesartan is an angiotensin II receptor blocker with an inhibitory efect on angiotensin-converting enzyme. Hypertens Res 2006; 29: 865-874.
23. Chen J, Xiao X, Chen S, Zhang C, Chen J, Yi D, Shenoy V, Raizada MK, Zhao B, Chen Y. Angiotensin-converting enzyme 2 priming enhances the function of endothelial progenitor cells and their therapeutic ef-cacy. Hypertension 2013; 61:681-689.
24. Xiao Q, Kiechl S, Patel S, Oberhollenzer F, Weger S, Mayr A, Metzler B, Reindl M, Hu Y, Willeit J, Xu Q. Endothelial progenitor cells, cardiovascular risk factors, cytokine levels and atherosclerosis-results from a large population-based study. PLoS One 2007; 2:e975.
25. Chiang CH, Huang PH, Chung FP, Chen ZY, Leu HB, Huang CC, Wu TC, Chen J W, Lin SJ. Decreased circulating endothelial progenitor cell levels and function in patients with nonalcoholic fatty liver disease. PLoS One 2012; 7:e31799.